Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges

被引：107

作者：

Stern, Howard M. ^{[1
]}

机构：

[1] Genentech Inc, Dept Pathol Res, San Francisco, CA 94080 USA

来源：

SCIENCE TRANSLATIONAL MEDICINE | 2012年 / 4卷 / 127期

关键词：

GROWTH-FACTOR RECEPTOR; HER2-OVEREXPRESSING BREAST-CANCER; TRASTUZUMAB PLUS DOCETAXEL; KINASE INHIBITOR; OPEN-LABEL; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; COMPLEX-FORMATION; GASTRIC-CANCER;

D O I：

10.1126/scitranslmed.3001539

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Amplification of the ERBB2 gene, which encodes human epidermal growth factor receptor 2 (HER2), causes the overexpression of a major proliferative driver for a subset of breast and gastric cancers. Treatments for patients with HER2-positive cancer include the monoclonal antibody trastuzumab and, in the case of metastatic breast cancer, the tyrosine kinase inhibitor lapatinib. Despite significant improvement in patient outcome as a result of these therapies, challenges remain. This Review focuses on proposed mechanisms of action and resistance in the context of potential new therapeutic options. Therapeutic approaches currently in development likely will yield additional clinically meaningful improvements for patients with HER2-positive cancer.

引用

页数：10

共 60 条

[1]

Bang YJ, 2010, LANCET, V376, P1302

[2] Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer [J].

Barok, Mark ;

Tanner, Minna ;

Koninki, Katri ;

Isola, Jorma .

CANCER LETTERS, 2011, 306 (02) :171-179

[3] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].

Baselga, Jose ;

Bradbury, Ian ;

Eidtmann, Holger ;

Di Cosimo, Serena ;

de Azambuja, Evandro ;

Aura, Claudia ;

Gomez, Henry ;

Dinh, Phuong ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Goldhirsch, Aron ;

Chang, Tsai-Wang ;

Horvath, Zsolt ;

Coccia-Portugal, Maria ;

Domont, Julien ;

Tseng, Ling-Min ;

Kunz, Georg ;

Sohn, Joo Hyuk ;

Semiglazov, Vladimir ;

Lerzo, Guillermo ;

Palacova, Marketa ;

Probachai, Volodymyr ;

Pusztai, Lajos ;

Untch, Michael ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine .

LANCET, 2012, 379 (9816) :633-640

[4] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Kim, Sung-Bae ;

Im, Seock-Ah ;

Hegg, Roberto ;

Im, Young-Hyuck ;

Roman, Laslo ;

Pedrini, Jose Luiz ;

Pienkowski, Tadeusz ;

Knott, Adam ;

Clark, Emma ;

Benyunes, Mark C. ;

Ross, Graham ;

Swain, Sandra M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119

[5] A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].

Berns, Katrien ;

Horlings, Hugo M. ;

Hennessy, Bryan T. ;

Madiredjo, Mandy ;

Hijmans, E. Marielle ;

Beelen, Karin ;

Linn, Sabine C. ;

Gonzalez-Angulo, Ana Maria ;

Stemke-Hale, Katherine ;

Hauptmann, Michael ;

Beijersbergen, Roderick L. ;

Mills, Gordon B. ;

de Vijver, Marc J. van ;

Bernards, Rene .

CANCER CELL, 2007, 12 (04) :395-402

[6] Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J].

Blackwell, Kimberly L. ;

Burstein, Harold J. ;

Storniolo, Anna Maria ;

Rugo, Hope ;

Sledge, George ;

Koehler, Maria ;

Ellis, Catherine ;

Casey, Michelle ;

Vukelja, Svetislava ;

Bischoff, Joachim ;

Baselga, Jose ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1124-1130

[7] Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells [J].

Browne, B. C. ;

Crown, J. ;

Venkatesan, N. ;

Duffy, M. J. ;

Clynes, M. ;

Slamon, D. ;

O'Donovan, N. .

ANNALS OF ONCOLOGY, 2011, 22 (01) :68-73

[8] Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy [J].

Burris, Howard A., III ;

Rugo, Hope S. ;

Vukelja, Svetislava J. ;

Vogel, Charles L. ;

Borson, Rachel A. ;

Limentani, Steven ;

Tan-Chiu, Elizabeth ;

Krop, Ian E. ;

Michaelson, Richard A. ;

Girish, Sandhya ;

Amler, Lukas ;

Zheng, Maoxia ;

Chu, Yu-Waye ;

Klencke, Barbara ;

O'Shaughnessy, Joyce A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) :398-405

[9] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer [J].

Burstein, Harold J. ;

Sun, Yan ;

Dirix, Luc Y. ;

Jiang, Zefei ;

Paridaens, Robert ;

Tan, Antoinette R. ;

Awada, Ahmad ;

Ranade, Anantbhushan ;

Jiao, Shunchang ;

Schwartz, Gary ;

Abbas, Richat ;

Powell, Christine ;

Turnbull, Kathleen ;

Vermette, Jennifer ;

Zacharchuk, Charles ;

Badwe, Rajendra .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1301-1307

[10] Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer [J].

Catzavelos, C ;

Bhatacharya, N ;

Ung, YC ;

Wilson, JA ;

Roncari, L ;

Sandhu, C ;

Shaw, P ;

Yeger, H ;

MoravaProtzner, I ;

Kapusta, L ;

Franssen, E ;

Pritchard, KI ;

Slingerland, JM .

NATURE MEDICINE, 1997, 3 (02) :227-230

← 1 2 3 4 5 6 →